Menu
The CaRE2-Grad+ Program of the Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center is a collaboration among Florida A&M University, a minority serving institution (MSI), University of Florida, and University of Southern California. The CaRE2-Grad+ Program aims to meet the cancer research education needs of underrepresented minorities (URM) in Florida and California, especially Blacks and Latinos, by offering academic career development, mentorship, networking opportunities, and tailored education opportunities in cancer health disparities, with the objective of supporting career advancement for PhD students, post-doctoral fellows and early-stage investigators.
Participating as a pre-doctoral student, postdoctoral fellow, or early stage investigator in research at FAMU, UF or USC
Dedicated to a career in cancer-related biomedical research career in basic, biomedical, clinical and behavioral sciences.
CaRE2 Grad+, our training program that provides academic career development, mentorship, and tailored cancer disparities research education opportunities for URM graduate students, postdoctoral fellows and early stage investigators (ESIs).
Your application and supporting documentation should be submitted on line via the application below.
CaRE Grad+ applications are open year round.
Postbac-CaRE2 applications for years 2022/2023 are open now and you are highly encouraged to submit your application by Friday, April 22, 2022.
For Grad+ applicants:
(1) a 1-page description of your career goals and objectives, personal attributes and motivations and desire for further training to focus on cancer health disparities research.
In addition, for Grad+ applicants who are PhD students and postdoctoral fellows:
(2) a statement of support for joining CaRE2 from your mentor, on letterhead and signed by your mentor.
For more information, contact:
Dr. Bereket Mochona: bereket.mochona@famu.edu
Dr. John Allen: john.allen@cop.ufl.edu
Dr. Ite Offringa: ilaird@usc.edu
Stay up to date with the latest news and information about Care2
